Biodesix Inc (BDSX) Stock AnalysisBDSXStock AnalysisBiodesix Inc

Biodesix, Inc. is a diagnostic solutions company. The Company's business includes Biodesix Lung Diagnostic Testing and Biodesix Development Services. Its Biodesix Lung Diagnostic Testing provides lung diagnostic testing services for healthcare providers through five blood-based tests. Its Biodesix Development Services supports global biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that enable the development of diagnostic tests, tools, and therapeutics. The Company offers Nodify Lung tests and IQLung tests that assess cancer risk and provide treatment guidance following a lung cancer diagnosis. The Nodify Lung tests include Nodify CDT and Nodify XL2 tests, which evaluate the risk of lung cancer in lung nodules. The GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests are used in the diagnosis of lung cancer to detect tumor mutations and assess the patient’s immune system status. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Biodesix Inc is a good buy right now due to its current price of $26.83, which is below the analyst price target of $32 from Roth Capital. The company has shown strong revenue growth of 34% in Q2, increasing to $26.9 million, and a gross margin of 82.06%, indicating solid profitability potential. However, the main risk is the negative net income, which was -$7.27 million in Q2 2026, highlighting ongoing losses that investors should monitor closely.